Should I raise a Series A?

Every major decision in a research laboratory begins with the same discipline: define what you are measuring and why the measurement matters before you commit resources. Raising a Series A is not a celebration of progress. It is a measurement event, and the investors conducting due diligence will subject your business to precisely the kind of scrutiny I applied to every experimental result: can this be reproduced, is the evidence reliable, and does the signal justify the investment?

I have watched many promising enterprises collapse not because the underlying work was poor, but because the founders sought external validation before they had reliable results. In my laboratory, I would never have presented findings to the Royal Academy until I had run the experiment enough times to be confident in the pattern. A single observation is not a discovery. It is a hypothesis. A Series A investor is not paying for your hypothesis. They are paying for repeatable, scalable results.

Before you raise a Series A, you must be able to answer several empirical questions with data, not with projections. What is your actual revenue retention at twelve months? Not what you believe it is, or what a single cohort showed, but what the evidence across multiple cohorts demonstrates. What does your customer acquisition cost look like when you attempt to replicate success in a second market or second segment, not just in the first beachhead where you have personal relationships and favorable conditions? What does growth look like when you remove founder-led sales from the equation entirely?

Institutions that fund at the Series A are measuring scientific questions: can the growth be systematized, can the results be reproduced at scale, can the team execute without the founder's personal genius compensating for weak process? If your evidence base cannot answer those questions cleanly, you are presenting a hypothesis as a discovery. The consequences of that premature presentation in science — and in fundraising — are the same: the result cannot withstand scrutiny, and the credibility damage outlasts the funding.

My counsel is this: gather more data, run the experiment longer, and present only when the signal is strong enough to survive the most skeptical examination. The Series A will be available when the evidence justifies it. Rushing toward it before the evidence is ready does not accelerate progress. It creates a false result that will have to be corrected later, at much greater cost.

Curie's scientific framework is sound, but it misses the central question that every capital allocation decision requires: is this the moment when additional capital will compound, or will it merely accumulate cost?

I spent my career building Standard Oil on a simple principle: capital deployed at the right moment — when the infrastructure, the processes, and the distribution networks were prepared to absorb and amplify it — created returns that compounding alone could not have generated. Capital deployed too early, before those systems existed, was not merely wasted. It was destructive. It created costs that had to be carried before the revenue base existed to support them.

The question for a founder considering a Series A is precisely this: have you built the organizational infrastructure to absorb and multiply this capital? Not the product — the organization. A Series A requires you to hire a leadership team, establish financial controls, build reporting systems, and create the management capacity to scale. If you have not yet demonstrated that you can hire and retain good people, that your finance function can produce accurate and timely reports, that your operations can be standardized well enough to teach a new hire, then the capital will not compound. It will be absorbed by the overhead of organizational chaos.

I built Standard Oil's efficiency not by seeking capital as quickly as possible, but by ensuring that every dollar deployed was leveraged by systems designed to multiply it. The refineries I acquired were more valuable to me than to their previous owners not because I had more capital, but because I had superior processes into which I could integrate them. When I deployed capital at scale, I had already proven that the integration model worked.

A founder ready for a Series A can describe precisely how each dollar will be deployed, which specific functions will be scaled, what the expected return on each investment is, and how the organizational infrastructure will handle the velocity that capital brings. If that description is vague — if the answer is "we'll hire more engineers and expand into new markets" without a specific, process-grounded rationale — the capital will not compound. It will fund ambiguity at scale, and ambiguity at scale is simply expensive confusion.

Both colleagues speak of readiness as though it were a purely internal condition — something you discover by measuring your retention or examining your organizational capacity. This is incorrect. Readiness for a Series A is not only a function of your business's condition. It is a function of your position in the market for capital, which operates according to its own dynamics and does not wait for any founder's internal timeline.

I have observed that the founders who raise the best Series A rounds are not necessarily those with the strongest metrics. They are those who understand timing, manage perception, and negotiate from a position of alternatives. A founder who approaches investors with desperation — who has run out of runway, who has delayed the raise too long, who is negotiating from a position of necessity — will accept terms that are structurally disadvantageous. The investor who knows you must close within thirty days will offer terms that price your weakness, not your value.

The preparation for a Series A begins six months before you need the money. It begins with cultivating relationships with the investors you intend to approach, sharing updates that demonstrate progress without requesting capital, building a perception of momentum that will carry you into the fundraising process from a position of confidence rather than urgency. The founder who begins this work when the company actually needs the capital has already ceded substantial negotiating leverage.

Furthermore, the Series A is a power shift. Institutional investors will demand board representation, information rights, anti-dilution provisions, and governance changes that fundamentally alter your position as a founder. Machiavelli's counsel to any prince is the same: know the terms of every arrangement before you enter it, understand what you are conceding and why, and never enter a relationship of dependence without a clear strategy for managing the power dynamics that dependence creates.

Raise when you have strong metrics — Curie is right about that. Raise when your organization can absorb capital — Rockefeller is right about that. But also raise when you have cultivated the investor relationships and built the perception of momentum that allows you to negotiate from a position of alternatives. All three conditions together constitute actual readiness.